Acutus Sells Left-Heart Access Business To Medtronic; Extends Its Cash Runway
The deal, potentially worth more than $85m, will allow Acutus to get more revenue from its core AcQMap electrophysiology mapping technology and invest in the development of its pulsed field ablation system.
You may also be interested in...
In an interview with Medtech Insight, Angelo De Rosa, the general manager of Boston Scientific’s cardiac rhythm management and electrophysiology businesses in Europe, Middle East and Africa (EMEA), discussed some of his company’s recent achievements and the opportunities it is addressing in 2022.
Analysts believe the company’s arrythmia mapping technology could potentially disrupt the electrophysiology mapping market, but are disappointed with Acutus’ growth so far.
ATP, a venture capital firm focused on life sciences, is providing the series A round to help Galaxy complete European and Canadian trials of its Centauri pulsed field ablation technology to treat atrial fibrillation.